Avinger (AVGR) Stock Price, News & Analysis

Company Overview

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.

Key Stats

• Today's Range: $0.93 to $1.08
• 50-Day Range: $0.98 to $1.77
• 52-Week Range: $0.90 to $14.00
• Volume: 918,456 shs
• Average Volume: 90,403 shs
• Market Capitalization: $1.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Avinger Stock Analysis - MarketRank™

Avinger scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Avinger has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Avinger has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Avinger are expected to grow in the coming year, from ($4.69) to ($1.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Avinger is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avinger is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.15% of the float of Avinger has been sold short.

Short Interest Ratio / Days to Cover

Avinger has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avinger has recently decreased by 1.91%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avinger does not currently pay a dividend.

Dividend Growth

Avinger does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.15% of the float of Avinger has been sold short.

Short Interest Ratio / Days to Cover

Avinger has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avinger has recently decreased by 1.91%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.70

News Sentiment

Avinger has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Avinger this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for AVGR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avinger insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.40% of the stock of Avinger is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 18.30% of the stock of Avinger is held by institutions.

AVGR Stock Analysis - Frequently Asked Questions

How have AVGR shares performed this year?

Avinger's stock was trading at $2.71 at the beginning of the year. Since then, AVGR stock has decreased by 62.7% and is now trading at $1.01.
View the best growth stocks for 2024 here.

How were Avinger's earnings last quarter?

Avinger, Inc. (NASDAQ:AVGR) issued its quarterly earnings results on Thursday, August, 8th. The medical device company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $2.39. The medical device company earned $1.85 million during the quarter, compared to analysts' expectations of $2.55 million.

When did Avinger's stock split?

Avinger's stock reverse split on the morning of Wednesday, September 13th 2023. The 1-15 reverse split was announced on Wednesday, September 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Avinger IPO?

Avinger (AVGR) raised $60 million in an initial public offering on Friday, January 30th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company served as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers.

Who are Avinger's major shareholders?

Avinger's top institutional investors include Armistice Capital LLC (2.57%). Insiders that own company stock include Nabeel Paul Subainati and James Cullen.
View institutional ownership trends.

How do I buy shares of Avinger?

Shares of AVGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Avinger own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avinger investors own include Bionano Genomics (BNGO), Novan (NOVN), Titan Pharmaceuticals (TTNP), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Organigram (OGI) and Onconova Therapeutics (ONTX).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 9/18/2024
• Next Earnings (Estimated): 10/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:AVGR
• CUSIP: N/A
• CIK: 1506928
• Web: www.avinger.com
• Phone: (650) 241-7900
• Fax: 800-229-2696
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +367.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($18.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-18,320,000.00
• Net Margins: -260.86%
• Pretax Margin: -260.86%
• Return on Equity: N/A
• Return on Assets: -117.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.66
• Quick Ratio: 1.20

Sales & Book Value

• Annual Sales: $7.43 million
• Price / Sales: 0.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.53) per share
• Price / Book: -0.24

Miscellaneous

• Outstanding Shares: 1,702,000
• Free Float: 1,508,000
• Market Cap: $1.82 million
• Optionable: Not Optionable
• Beta: 1.17